Lyra Therapeutics, Inc. (LYRA) has a consensus analyst rating of Hold, based on 5 analysts covering the stock. Of those, 2 recommend buying, 3 recommend holding, and 0 recommend selling.
The analyst consensus price target for LYRA is $0.50, representing a +13.6% upside from the current price of $0.4401. Price targets range from a low of $0.50 to a high of $0.50.
